Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37384 | 0.79 | DPP4 (0.66) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL11456967 | 0.78 | DPP4 (0.63) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL8719273 | 0.78 | DPP4 (0.63) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| Hydrochloric Acid SCHEMBL4763244 | 0.78 | DPP4 (0.63) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL24500763 | 0.76 | XDH (0.56) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL9733146 | 0.76 | XDH (0.56) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL5935896 | 0.76 | CDK2 (0.61) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL4451634 | 0.76 | XDH (0.61) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL1009011 | 0.76 | XDH (0.56) | XDHDPP4KDM4ESMN1; SMN2TMIGD3 | |
| SCHEMBL2867588 | 0.76 | PDPK1 (0.66) | DPP4PDPK1GDACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | XDH 2012/4885DPP4 206/4885KDM4E 1834/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | XDH 2012/4885DPP4 206/4885KDM4E 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.